OMCL — Omnicell Inc
NASDAQ · Healthcare · Health Information Services
$34.59
+$0.08 (+0.22%)
Omnicell Inc (OMCL) is a health information services company listed on NASDAQ. It is led by Randall A. Lipps, based in 4220 North Freeway, Fort Worth, TX, United States, 76137, with about 3,525 employees. Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Latest reported OMCL revenue for 2025-09-30 was $310.6M. Net income was $5.5M. Revenue was up 6.9% from 2025-06-30 to 2025-09-30. OMCL currently screens at market cap $1.80B and trailing P/E 89.9.
Use this OMCL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OMCL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OMCL SEC filings page. Lician reads the product cache first so this HTML stays unique to Omnicell Inc even when a live quote feed is slow.
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OMCL Key Statistics
Market Cap
$1.80B
Volume
665,912
Previous Close
$34.66
Day Range
$33.16 – $34.91
P/E Ratio
89.91
P/B Ratio
1.44
EPS
$0.27
Revenue
$1.11B
Net Income
$12.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-3.0%
Profit Margin
1.1%
Employees
3,525
OMCL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.11B | $1.15B | $1.30B | $1.13B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $12.53M | -$20.37M | $5.65M | $77.85M |
| EPS (Diluted) | $0.27 | -$0.45 | $0.12 | $1.62 |
Total Assets
$2.12B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$369.20M
Operating Cash Flow
$187.72M
Free Cash Flow
$0.00
Omnicell Inc Company Information
- Founder, Executive Chairman, President & CEO
- Randall A. Lipps
- Headquarters
- 4220 North Freeway, Fort Worth, TX, United States, 76137
- Website
- www.omnicell.com
- Phone
- 877 415 9990
- IPO / Founded
- 2001-08-07
- Sector
- Healthcare
- Industry
- Health Information Services